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The pyridoxal 5󸀠-phosphate (PLP)-dependent enzyme serine palmitoyltransferase (SPT) catalyses the first step of de novo
sphingolipid biosynthesis. The core human enzyme is a membrane-bound heterodimer composed of two subunits (hLCB1 and
hLCB2a/b), and mutations in both hLCB1 (e.g., C133W and C133Y) and hLCB2a (e.g., V359M, G382V, and I504F) have been
identified in patients with hereditary sensory and autonomic neuropathy type I (HSAN1), an inherited disorder that affects sensory
and autonomic neurons. These mutations result in substrate promiscuity, leading to formation of neurotoxic deoxysphingolipids
found in affected individuals. Here we measure the activities of the hLCB2a mutants in the presence of ssSPTa and ssSPTb and
find that all decrease enzyme activity. High resolution structural data of the homodimeric SPT enzyme from the bacterium
Sphingomonas paucimobilis (Sp SPT) provides a model to understand the impact of the hLCB2a mutations on the mechanism of
SPT.The three human hLCB2a HSAN1 mutations map onto Sp SPT (V246M, G268V, and G385F), and these mutant mimics reveal
that the amino acid changes have varying impacts; they perturb the PLP cofactor binding, reduce the affinity for both substrates,
decrease the enzyme activity, and, in the most severe case, cause the protein to be expressed in an insoluble form.
1. Introduction
Sphingolipids (SLs) are membrane components found in all
eukaryotes, some prokaryotes, and viruses. SLs and their
downstream metabolites (such as ceramide) play important
roles in mediating cell-stress response and cell proliferation
and in regulating the cell cycle and apoptosis [1–3]. Deficien-
cies in SLmetabolismhave been implicated in several diseases
that include cancer and diabetes, as well as neurodegenerative
disorders such as Alzheimer’s [4, 5]. The first enzyme of the
de novo sphingolipid biosynthetic pathway present in all SL-
producing organisms is the pyridoxal 5󸀠-phosphate- (PLP-)
dependent serine palmitoyltransferase ((SPT) EC 2.3.1.50)
[6]. It catalyses the condensation of L-serine with palmitoyl
coenzyme-A to generate 3-ketodehydrosphinganine (KDS)
that forms the sphingoid base backbone of all SLs. The 3D
structure of the soluble, homodimeric SPT from the SL-
producing organism S. paucimobilis (Sp SPT) was published
by our group in 2007. It is a member of the PLP superfamily
(fold type I) and contains three domains: N-terminal, central,
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and C-terminal [7]. Based on extensive structural and bio-
chemical analyses of this enzyme, a working SPTmechanism
involves the formation of a number of key intermediates
(Figure 1) [7]. An initial PLP-bound internal aldimine (cova-
lently attached to Lys265) is displaced by L-serine to generate
a PLP:L-serine external aldimine. Binding of the C16 acyl-
CoA thioester allows formation of a carbanion/quinonoid
nucleophile by deprotonation of the external aldimine. After
Claisen-like condensation, a 𝛽-keto acid is formed which
subsequently loses CO
2
to generate a PLP:KDS product
aldimine which is then released from the enzyme, and the
SPT returns to its PLP-bound internal aldimine form.We and
others have investigated the catalytic roles of conserved active
site SPT residues in this mechanism [8–11].
Eukaryotic SPT is a membrane-bound enzyme which
contains two core subunits, LCB1 and LCB2 in yeast [12–14]
and SPTLC1 and SPTLC2/3 in mammals [15–17]. For clarity
we have adopted the nomenclature hLCB1, hLCB2a/b for
the human subunits [18]. The hLCB1 and hLCB2 subunits
display relatively high sequence homology to each other, but
a comparison with other PLP-binding enzymes revealed that
only the hLCB2a contains key catalytic residues including
the lysine that binds PLP [19, 20]. In contrast, hLCB1 lacks
these residues but contains other residues predicted to be
involved in catalysis leading to the working hypothesis that
the hLCB1/hLCB2a heterodimer has a single active site.
Hornemann and colleagues suggested that the eukaryotic
SPT may in fact be a higher order complex [21], and indeed
recent results lend weight to that hypothesis. Also, the same
group recently identified a second hLCB2 isoform, hLCB2b,
also known as SPTLC3with 68% sequence identity to hLCB2a
that is predominantly expressed in the placenta and prefers
shorter chain acyl-CoAs (C12 and C14) to generate short-
chain SLs [22]. We identified two highly-related isoforms
of a third “small subunit” in humans (ssSPTa and ssSPTb)
which were shown to be crucial for maximal enzyme activity
[18]. These are functionally orthologous to a previously-
characterised small subunit (Tsc3p) discovered in yeast [23].
These ssSPTs can increase the catalytic activity of the hLCB1/
hLCB2 complex up to 100 fold, and also influence the chain-
length specificity of the acyl-CoA substrate, and, thus, impact
directly on the concentrations and chemical nature of the
SL pool. This complexity was further increased by the recent
discovery of other components of a so-called SPOTS complex
in yeast that is composed of LCB1/LCB2/Tsc3p, an ORM
protein(s), and a phosphoinositide phosphatase, Sac1 [24, 25].
These ORM and Sac1 components are thought to play a role
in modulating SPT activity and flux through the SL pathway
by a phosphorylation-dependent mechanism [25–28].
Since SLs and ceramides are essential elements of cellular
membranes that also play important roles in cell signalling,
homozygous LCB1/LCB2 mutations that cause complete loss
of SPT activity would be assumed to be lethal. However, there
are very rare gain-of-function SPT mutations that have been
identified and their genetic lineage has been studied [29–33].
These SPTmutations lead to hereditary sensory neuropathies
(HSAN1) whose clinical outcomes include progressive distal
sensory loss and severe ulcerations of the limbs. What causes
the neuronal breakdown has been the subject of interesting
debate. As well having an impact on the basal SPT activity, a
new hypothesis suggests that the SPT mutations associated
with HSAN1 lead to an enzyme lacking exquisite substrate
specificity for L-serine. Penno and colleagues discovered
that tissue from HSAN1 patients contains high levels of L-
alanine and glycine-derived deoxy-SLs that have been shown
to be toxic to HEK293 cells [32]. Four missense mutations in
the hLCB1 subunit associated with HSAN1 (C133W, C133Y,
V144D, and G387A) were among the first to be identified
(Table 1) and have shown to have a negative effect on the
SPT enzyme and sphingolipid production [29, 30, 34, 35].
Another mutation at residue C133 (C133R) was identified
in a patient with a mild phenotype, but its impact on SPT
activity has not been characterized [36]. The multisubunit,
membrane-bound nature of the eukaryotic SPT has pre-
vented a detailed structural and mechanistic analysis of the
impact of the HSAN1 causing mutations on the enzyme.
To gain insight into and explore the molecular basis of the
HSAN1 genotype we have used the Sp SPT isoform as amodel
system. Both cysteine mutations were previously engineered
into the Sp SPT (as N100W and N100Y) in our group
[10]. These mutations result in a compromised SPT enzyme,
severely impacting PLP binding, reducing affinity for the L-
serine substrate, and causing catastrophic effects on catalytic
activity. More recently, two more hLCB1 mutations (S331F
and A352V) were identified. The S331F mutation resulted in
symptoms far more severe than those associated with the
more common HSAN1 mutations. Furthermore, a second
mutation at amino acid position Ser331 (S331Y) is linked to
a distinct syndrome phenotype [37, 38]. Interestingly, for the
first time, three different mutations (V359M, G382V, and
I504F) were recently identified in the hLCB2a subunit by
Rotthier et al. [39]. They found that each mutation lowered
the activity of the hLCB1/hLCB2a heterodimer and was also
able to generate varying levels of deoxy-SLs. This group also
modelled the three hLCB2a mutations onto the bacterial Sp
SPT (V246M, G268V, and G385F) paving the way for the
biochemical analysis that we describe here (Figure 2). In this
report, we have studied the influence of the human small
subunits on the activity of the HSAN1 hLCB2a mutations. As
well as this, we have also characterised the bacterial mutant
mimics using enzyme kinetics, spectroscopy, and molecular
modelling to provide insight into the impact they have onPLP
cofactor binding, catalytic activity, and/or substrate binding.
2. Materials and Methods
2.1. Chemicals and Molecular Biology Materials. Plasmids
and competent cells were purchased from Novagen. All
buffers and reagents were from Sigma. Palmitoyl-CoA was
purchased from Avanti Lipids.
2.2. Methods
2.2.1. Analysis of Human SPT Wild Type and HSAN1 Mutant
Activity in the Presence of the ssSPTa and ssSPTb Subunits.
The construction of yeast mutant strains lacking lcb1, lcb2,
and tsc3 was described previously [18, 31]. Yeast microsomes
were prepared, and expression of recombinant human forms
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Table 1: Overview of currently known hLCB1 and hLCB2a HSAN1 related mutations.
Mutant Sp SPT residue Location in Sp SPT Clinical features Reference
hSPT1
C133Y N100 Active site Sensory neuropathy, ulceromutilations,and lancinating pains. [29, 30]
C133W N100 Active site Sensory neuropathy, ulceromutilations,and lancinating pains. [29, 30]
C133R N100 Active site Sensory neuropathy. [36]
V144D D121 Surface exposed Sensory neuropathy, ulceromutilations,and lancinating pains. [30]
S331F H278 Surface exposed
Ulcerations, mental retardation,
hypotonia, severe growth and mental
retardation, vocal cord paralysis, and
gastroesophageal reflux.
[33, 37]
S331Y H278 Surface exposed As S331F. [38]
A352V S308 Not surface exposed Sensory neuropathy, ulceromutilations,and lancinating pains. [33, 37]
G387A E343 Surface exposed No disease associated. [40, 41]
hSPT2
V359M V246 Not surface exposed Sensory neuropathy, ulceromutilations. [39]
G382V G268 Active Site Sensory neuropathy, ulceromutilations. [39]
I504F G385 Surface exposed Sensory neuropathy, ulcerations,osteomyelitis, and anhidrosis. [39]
A182P T79 Not surface exposed Sensory neuropathy. [42]
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Figure 1: Proposed SPT mechanism. (a) Transamination of internal aldimine by incoming L-serine to form PLP-L-serine external aldimine
intermediate; (b) binding of palmitoyl-CoA causes conformational change and deprotonation of external aldimine by Lys265 to form
quinonoid/carbanion intermediate; (c) quinonoid/carbanion attack of the thioester; (d) formation of 𝛽-keto acid and CoASH release; (e)
release of CO
2
to formKDS product quinonoid; (f) reprotonation of KDS; (g) transamination to release KDS and restore the internal aldimine
with PLP-bound to Lys265.
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Figure 2: High resolution structure of Sp SPT homodimer PLP-L-
serine external aldimine showing the position of the three hLCB2a
HSAN1 related mutations (PDB:2W8J). Each monomer is coloured
(red and yellow). Sequence alignment of bacterial Sp SPT (Uniprot
code: Q93UV0) with bacterial Sw SPT (Uniprot code: A5VD79) and
human hLCB2a (Uniprot code: O15270). The key catalytic lysine
residue (K265) involved in the formation of the internal aldimine
is coloured red, and the HSAN1 mutant mimics (V246M, G268V,
and G385F) are coloured cyan.
of each subunit, hLCB1, hLCB2a, ssSPTa, or ssSPTb, was visu-
alised by immunoblotting using antibodies directed against
hLCB1, hLCB2a, and the HA epitope as previously described
[18]. Yeastmicrosomal SPT activity was assayed bymeasuring
[3H] serine incorporation into long chain bases as previously
described [18].
2.2.2. Bacterial SPT Gene Cloning andMutagenesis. Theplas-
mid (pET 28a/Sp SPT) that we use to express S. paucimobilis
SPT in E. coli was available at the start of this study and
contains a six-histidine tag at the C-terminus [10]. This was
used as a template, and all HSAN1 mutations were made
using the Liu and Naismith [43] mutagenesis protocol with
the following primers:
5󸀠CGGCATGTACGAGGCGCAAG 3󸀠 (V246M for-
ward)
5󸀠TCGTACATGCCGCGCCCGTTG 3󸀠 (V246M
reverse)
5󸀠GGTCGTCACAGTCGGCGGCTTC 3󸀠 (G268V
forward)
5󸀠ACTGTGACGACCGATTTGGAG 3󸀠 (G268V
reverse)
5󸀠CGGCCTTCACCTTCCTGCTG 3󸀠 (G385F for-
ward)
5󸀠AAGGTGAAGGCCGGGGTC 3󸀠 (G385F reverse).
The bases mutated are shown in bold and italic. The isolated
mutants were verified by DNA sequencing and mass spec-
trometry analysis of the purified enzyme.
2.2.3. Cloning and Expression of Sphingomonas paucimo-
bilis SPT (Sp SPT) and HSAN1 Mutant Mimics. The Sp
SPT enzyme was prepared as previously described [10].
A single colony pET28a Sp SPT was grown overnight at
37∘C in LB selected with kanamycin (30 𝜇g/mL) using E.
coli BL21 (DE3) cells. The culture was diluted 1 : 100 into
fresh LB/kanamycin solution and grown to an OD
600
of
0.6. Expression was induced with the addition of 0.1mM
isopropyl-𝛽-D-1-thiogalactopyranoside (IPTG) and grown at
30∘C, 200 rpm. Harvested cells were resuspended in lysis
buffer, 20mM potassium phosphate, pH 7.5, 150mM NaCl,
10mM imidazole, 25 𝜇M PLP, and a protease inhibitor cock-
tail (Roche). Cells were lysed by sonication on ice (Soniprep
150, 15 cycles of 30 seconds on followed by 30 seconds off).
The lysate was centrifuged for 25 minutes at 16,000 rpm.
The resulting supernatant was incubatedwith preequilibrated
Ni resin (Ni-NTA Superflow, Qiagen) for 1 hour at 4∘C.
The protein eluted with 300mM imidazole and was further
purified by gel filtration (S200 HR, GE Healthcare) using
20mM potassium phosphate, pH 7.5, 150mM NaCl, and
25 𝜇M PLP buffer.
2.2.4. Spectroscopic and Kinetic Measurements of Bacterial
SPTs. All UV-visible spectra were recorded on Cary 50 UV-
visible spectrophotometer (Varian) and analysed using Cary
WinUV software (Varian). Prior to all UV-visible spectro-
scopies and assays, SPT was dialysed against fresh buffers
containing 250 𝜇M PLP to ensure that the enzyme was in
the PLP bound, holoform. Excess PLP was removed on a
PD-10 (SephadexG-25M) desalting column (GEHealthcare).
For UV-visible assays the concentration of enzyme was
40 𝜇M, and the spectrophotometer was blanked with 20mM
potassium phosphate (pH 7.5) containing 150mM NaCl at
25∘C.Quartz cuvettes fromNSGPrecisionCells, Type 18-BM,
with a light path of 10mm and a sample volume of 500𝜇L
were used, and the spectra were collected from 800 nm to
200 nm.The release of CoASH fromC16-CoASHduringKDS
formation was used to measure SPT activity as previously
described [10]. Assays were performed on a 200𝜇L scale on a
96-well format in a Biotek Synergy HT plate reader. Kinetic
constants were calculated using Michaelis-Menten kinetics
and using GraphPad Prism 6 software.
2.2.5. Bacterial SPT Enzyme Activity by Measuring KDS For-
mation. SPT activity was also monitored by incorporation of
[14C] L-serine into [14C]-KDS by a modification of a pub-
lished method [10]. A final enzyme concentration of 25𝜇M
SPT (in 20mM potassium phosphate buffer, pH 7.5, and
150mM NaCl) was incubated with 20mM U-14C L-serine
(7400 Bq, 0.2 𝜇Ci, PerkinElmer) and 250 𝜇M palmitoyl-CoA
in a final volume of 1mL. The reaction was incubated at
37∘C for 20 minutes, and then the reaction was quenched
by the addition of NH
4
OH (final concentration 0.4M). This
was then extracted with an equal volume of CHCl
3
: CH
3
OH
(2 : 1, v : v). The sample was centrifuged at 13,000 rpm for 5
minutes, and the aqueous phase was discarded. The organic
phase was left to evaporate at 50∘C.The resulting lipid residue
was resuspended in 15𝜇L of CHCl
3
: CH
3
OH (2 : 1, v : v) and
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spotted onto a Silica Gel 60 F
254
TLC plate. Separation was
carried out with a mobile phase of CHCl
3
: CH
3
OH (2 : 1,
v : v). The TLC plate was scanned with an AR-2000 imaging
scanner and [14C]-labelled products quantified using the
Laura 4 software (LabLogic).
2.2.6. Determination of Dissociation Constants, Substrate
and Product Quinonoid Detection, and SPT Activity Assays.
Binding assays typically contained 40 𝜇M enzyme in 20mM
potassium phosphate (pH 7.5). Varying amounts of L-serine
(0–40mM) were added, and after addition of the substrate,
the reaction mixture was allowed to equilibrate for 15min at
25∘C.The𝐾
𝑑
values were calculated fromplots ofΔ425 versus
L-serine concentrations by fitting to a hyperbolic saturation
curve using Sigma Plot software
Δ𝐴obs =
Δ𝐴max [serine]
𝐾
𝑑
+ [serine]
, (1)
where Δ𝐴obs represents the observed change in absorbance
at 425 nm, Δ𝐴max is the maximal absorbance change, [ser-
ine] represents L-serine concentration, and the 𝐾
𝑑
is the
dissociation constant. Also, the formation of the quinonoid
intermediate was followed. In this case, 50mM L-serine and
1.5mM S-(2-oxoheptadecyl)-CoA were mixed to the enzyme
(40 𝜇M) [10, 32], and the reactants were allowed to equilibrate
for 15min at 25∘C (data not shown).
3. Results
3.1. Enzymatic Activity of Wild Type and HSAN1 hLCB2a
Mutant SPT. In the report of the hLCB2a-causing HSAN1
mutants (V359M, G382V, and I504F), Rotthier et al.
expressed mutant hLCB2a subunits in human embryonic
kidney (HEK 293) cells and measured microsomal SPT
activity [39]. They noted that each mutation reduced enzyme
activity (above background) by different amounts (∼40–
100% activity) compared with wild type. In 2009, Han and
colleagues discovered small subunits of SPT (ssSPTa and
ssSPTb) that when coexpressed with hLCB1 and hLCBa
increased human SPT activity by 50–100-fold [18]. These
small subunit activators appear to play the same role as
the small yeast protein Tsc3p also discovered by Gable and
colleagues nearly ten years earlier [23]. To investigate the
effect of the small subunits on the new HSAN1-associated
hLCB2a mutants, we expressed each of the human mutant
genes in yeast cells which had had the endogenous sub-
units of SPT knocked out. This strain, which completely
lacks SPT activity, is not viable unless supplemented with a
long chain base or a competent, active SPT complex. The
yeastmicrosomes expressingwild-type hLCB1/hLCB2a in the
absence of either small subunit displayed very low activity (<5
pmoles serine incorporated/min/mg protein) as predicted
(Figure 3). Similarly, coexpression of each of the threeHSAN1
hLCB2a mutants (V359M, G382V, and I504F) along with
hLCB1 resulted in low activity, with G382V barely detectable
above backgroundmirroring the results reported by Rotthier
and colleagues. Their activity values are in CPM (14C)/𝜇g
protein so they are difficult to be compared with ours in
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Figure 3: SPT activity in yeast microsomes expressing hLCB1 (h1)
+ hLCB2a (h2a, wt, or HSAN1 mutants) in the presence or absence
of the small subunits ssSPTa (ssa) or ssSPTb (ssb).
absolute terms. When we coexpressed wild-type hLCB1 and
hLCB2a in the presence of either ssSPTa or ssSPTb, the
activity was indeed increased by 50–100-fold. Heterodimers
containing the V359M and G382V mutant hLCB2a subunits
were similarly activated by ssSPTa. In contrast heterodimers
containing the I504 mutant hLCB2a subunit were activated
to a lesser extent. When ssSPTb was expressed, heterodimers
containing the G382V and I504F mutant hLCB2a subunits
were activated to the same extent as wild-type heterodimers,
but heterodimers containing theV359Mmutant subunit were
less well activated. Our interpretation of these data is that
each of the new hLCB2a mutants had a small impact on SPT
activity and that each mutant enzyme is still activated by the
presence of the activating small subunits. The small impact
of these new mutants is in contrast to the C133W, C133Y,
and V144D mutations in hLCB1 but is similar to what was
observed in the recently reported S331F mutation in hLCB1
[44].
3.2. Expression and Purification of HSAN1 hLCB2a Mutant
Mimics. The three hLCB2a mutations that cause HSAN1
were individually introduced into the Sp SPT gene sequence
(Figure 2), and the three mutant proteins were expressed
using established protocols [10]. Two of the three mutants
(Sp SPT V246M and G385F) were soluble. In contrast,
the G268V mutant was found to be insoluble, and several
attempts were made to improve the solubility of the protein
(such as changing expression cell lines, induction at lower
temperature, and different IPTG concentrations (data not
shown)); however the majority of the protein remained in
the cell pellet suggesting that this particular HSAN1 hLCB2a
mutation leads to substantial protein misfolding of the
bacterial mimic. The other two mutants (Sp SPT V246M and
G385F) were obtained in milligram quantities and purified
via nickel affinity chromatography as previously described for
the wild-type SPT [10]. Both V246M and G385F behaved as
6 BioMed Research International
dimers by size exclusion chromatography (molecular weights
∼90 kDa) and displayed elution profiles similar to wild-type
SPT (data not shown).
3.3. Spectroscopic Properties of WT SPT and HSAN1 Mutant
Mimics. Formation and breakdown of many of the interme-
diateswithin the SPTmechanism (Figure 1) can bemonitored
by UV-visible spectroscopy due to the yellow colour of the
PLP-bound enzyme. Initial analysis of the Sp SPT V246M
(Figure 4(b)) and G385F (Figure 4(c)) by UV-visible spec-
troscopy revealed that both HSAN1 mutants display spectra
similar to wild-type SPT, with two absorbance maxima at
around 335 and 420 nm (Figure 4(a)).These peaks are charac-
teristic of the holo-, PLP-bound internal aldimine form of the
enzyme, arising from the two tautomeric forms (enolimine
and ketoenamine resp.) of PLP. These results confirm that
both mutants were purified with the PLP cofactor covalently
bound in the enzyme active site as an imine to Lys265.
However, on closer inspection it is clear that there are subtle
differences in the spectral profile of SPT G385F compared
with the wild-type enzyme. In contrast to the wild-type SPT,
the UV-visible spectrum of SPT G385F shows a significant
blue shift with maximum absorbance values of 330 nm and
410 nm (Figure 4(c)). This suggests that mutation at position
385 has had an impact on the way the PLP cofactor binds at
the active site.
The internal aldimine/PLP-bound form of SPT can be
displaced with increasing concentrations of the substrate
L-serine to form a SPT:PLP-L-serine external aldimine
which can be easily monitored by observing the change in
absorbance at 425 nm.Analysis of thewild-type SPT andboth
mutants led to the determination of the apparent L-serine
dissociation constants (𝐾
𝑑
ser, Table 2). Binding studies were
also carried out with L-alanine and glycine (data not shown).
At physiological concentrations, L-serine was able to form
the external aldimine in wild type and both mutant forms of
SPT. Wild-type SPT binds L-serine with a𝐾
𝑑
ser of 1.1mM (as
obtained previously, Raman et al. [10]), and a similar 𝐾
𝑑
ser
value of 1.5mM was obtained for the V246M mutant. This
analysis supports the initial observation (based onUV-visible
data) that PLP is bound in the same environment as that
of the wild-type enzyme. In contrast, a 𝐾
𝑑
ser of 4.7mM was
obtained for mutant G385F, a ∼4-fold increase in comparison
to the wild-type SPT, suggesting that this mutation has had
some impact on both PLP and substrate binding. We have
shown previously that the wild-type bacterial SPT is unable
to use glycine or L-alanine as substrates to allow formation of
deoxy-SLs to appreciable levels, and neither the V246M nor
G385Fmutant binds to L-alanine or glycine (data not shown).
3.4. Kinetic Analysis and KDS Formation of SPT WT and
HSAN1 Mutant Mimics. In order to ascertain the effect that
each of the HSAN1 hLCB2a mutant mimics has on enzyme
catalysis, Michaelis-Menten kinetic analyses were performed
for the wild-type V246M and G385F enzymes using a
DTNB assay that monitors formation of the CoASH product
(Figure 1). The wild-type SPT bound L-serine and palmitoyl-
CoA (C16-CoA) with 𝐾
𝑚
values of 1.6mM and 35.6 𝜇M,
respectively (Table 2). The enzyme turned over with a 𝑘cat of
1.14 s−1 and efficiency (𝑘cat/𝐾𝑚) of 712M
−1s−1 for L-serine and
32022M−1s−1 for the acyl-CoA—all in good agreement with
published values [10]. In contrast, wemeasured lower 𝑘cat/𝐾𝑚
values of 176 and 136M−1s−1 for L-serine (4- and 5-fold) and
3437 and 7854M−1s−1 for C16-CoA (9- and 4-fold lower) and
for the V246M and G385F mutants, respectively (Table 2). In
addition, we monitored product KDS formation directly by
using incorporation of 14C L-serine. Both mutants were less
active and displayed 84% (V246Mmutant) and 15% (G385F)
KDS production relative to the wild-type SPT enzyme.
3.5. Substrate Quinonoid Formation in SPT WT and HSAN1
Mutants. The ability of the wild-type enzyme and mutants
to generate a key carbanion/quinonoid species was tested
using the C16-CoA thioether analogue, S-(2-oxoheptadecyl)-
CoA. Addition of the analogue to the PLP-L-serine external
aldimine form of the wild-type SPT led to the appearance
of a peak at ∼495 nm which is thought to be the substrate
quinonoid [45]. Under the same conditions, both V246M
and G385F generate a quinonoid peak confirming that these
mutants can catalyse formation of this key intermediate (data
not shown).
3.6. Modelling the Structural Impact of HSAN1 Mutations.
Unfortunately, neither of the SPT V246M nor G385F HSAN1
mutant mimics crystallised (under the same conditions as
wild type [7, 10] or by screening for new conditions).
Therefore, to rationalise the impact that each of the HSAN1
hLCB2a mutations has on the structures of these altered
enzymes, modelling was carried out based upon the crystal
structure of holo-SPT (PDB:2JG2) [7] and the SPT:PLP-
L-serine external aldimine complex (PDB:2W8J) [10]. It is
worth noting that the PLP-binding site is at the subunit
interface between the two monomers, and the active site
is formed by residues from both subunits. We used the
“mutagenesis” tool within PyMol [46] to replace the wild-
type side chain with each mutant side chain and applied the
default conformational constraints to produce a structural
model. We chose to highlight interactions that were within
5 A˚ of eachmutant residue of interest.The amide backbone of
G268 makes polar contacts with the side chain of S97 and the
backbone of F263 and most importantly the backbone of the
crucial K265 residue involved in PLP binding (Figure 5). The
model predicts that these polar contacts to S97 and F263 are
maintained after inclusion of the isopropyl side chain of the
G268V mutant; however, it loses the polar contact with the
K265 residue. In addition to this, several new interactions are
predicted to occur within 5 A˚ of the V268 mutant side chain
in comparison to G268. The most interesting/important of
these is the additional contact made with the backbone of
M78 (from the same subunit) that leads to a severe steric
clash with the side chain of V268. This interaction is not
present in the wild-type structure and suggests that the bulky
hydrophobic valine residue cannot be accommodated at this
position. This structural change may well be the cause of the
observed detrimental effect on protein solubility.
Position G385 is shown to be on the surface of SPT and
solvent exposed (Figure 6). Mutation of this residue to F385
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Figure 4: UV-visible analysis of Sp SPT wild-type and mutant mimics. Absorbance spectra of (a) Sp SPT wild type, (b) SPT V246M, and
(c) SPT G385F. In the wild-type spectrum (a), the enolimine (335 nm) and ketoenamine (420 nm) forms of the external aldimine are shown.
The solid line in each spectrum is the holoform of the enzyme (40 𝜇M SPT, 20mM potassium phosphate buffer (pH 7.5), and 150mM NaCl,
25∘C). Increasing concentrations of L-serine were added (0, 0.5, 1, 2, 5, 10, 20, and 40mM; dotted and dashed lines), and the spectrum was
recorded after 15 minutes.
may result in this hydrophobic side chain preferring a buried
hydrophobic pocket. G385 resides in an important, con-
served SPT motif 379-PPATPAGTFLLR-390 that is known
to undergo conformational change during the catalytic cycle.
Residue R378 is known to bind the carboxylate of the L-serine
substrate in the PLP-L-serine external aldimine complex
and to do so undergoes large movement brought about by
the structural changes of the PPATP loop [10]. Mutation
8 BioMed Research International
Ser97
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Figure 5: Structural models of the HSAN1 mutant mimic Sp SPT G268V using the Sp SPT PLP-L-serine external aldimine structure
(PDB:2W8J). (a) Wild-type Sp SPT highlighting interactions within 5 A˚ of G268. (b) Mutated residue Val 268 showing new interactions
within 5 A˚. The models and figures were generated using PyMol software.
Gln250
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Gln250
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Figure 6: Structural models of HSAN1 mutant mimic Sp SPT V246M mutation using the Sp SPT-L-serine external aldimine structure
(PDB:2W8J). (a) Wild-type V246. (b) Mutation of residue 246 to a methionine. Residue 246 is shown in yellow. The models and figures
were generated using PyMol software.
of R378 impacts both substrate binding and catalysis; our
model suggests that the introduction of F385 would alter
the conformational flexibility of the enzyme. This is indeed
the case since we observed a ∼5-fold decrease in efficiency
(𝑘cat/𝐾𝑚
L-ser) of the G385F mutant compared with wild type
(Table 2).
The side chain of residue V246 is in a hydrophobic
pocket in close proximity to F239 and V204, and the amide
backbone makes polar contacts with the side chain of E232
and the backbone amides of A249 and Q250 (Figure 7). In
the model, mutation of this residue to a methionine does not
cause any severe alterations or clashes, and the M246 side
chain is accommodated in the same pocket. Nevertheless,
this mutation does have some impact on the palmitoyl-CoA
binding by reducing the 𝐾
𝑚
by ∼4-fold and (𝑘cat/𝐾𝑚
PCoA)
approximately by 9-fold.
4. Discussion
HSANs are a rare group of disorders of the peripheral nervous
system (PNS) [47]. They arise through a series of diverse
genetic mutations and present a broad range of clinical
symptoms. Overall, HSANs lead to neurodegeneration of the
PNS, and the current working hypothesis is that HSAN1
is caused by mutations in subunits of SPT that impact the
structure and function of the enzyme [29–31, 34, 48]. An
appreciation of the complexity of the eukaryotic SPT enzyme
has increased over the past 4-5 years with the identification of
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Figure 7: Structural models of the Sp SPT G385F mutant mimic. (a) Sp SPT holostructure (PDB:2JG2) and the L-serine external aldimine
structure (PDB:2W8J). Residues from monomer one are shown in white, residues from monomer two are shown in teal, the PLP cofactor is
shown in green, and the mutated glycine to phenylalanine residue is shown in yellow. The models and figures were generated using PyMol
software.
Table 2: Kinetic parameters of wild-type Sp SPT and mutants.
Enzyme 𝑘cat × 10
−2
(s−1)
𝐾
L-ser
𝑚
(mM)
𝐾
PCoA
𝑚
(𝜇M)
𝑘cat/𝐾
L-ser
𝑚
(M−1 s−1)
𝑘cat/𝐾
PCoA
𝑚
(M−1 s−1)
𝐾
L-ser
𝑑
(mM)
SPTWT 114 ± 2.0 1.6 ± 0.09 35.6 ± 2.0 712 32022 1.1 ± 0.1
SPT V246M 44 ± 1.2 2.5 ± 0.2 128.0 ± 10.0 176 3437 1.5 ± 0.1
SPT G385F 41 ± 2.0 3.0 ± 0.5 52.2 ± 8.0 136 7854 4.7 ± 0.1
SPT G268V — — — — — —
new regulatory subunits (such as the small subunits ssSPTa
and ssSPTb and the ORMs), but at its heart it requires
the homologous subunits hLCB1 and hLCB2a which come
together to form a heterodimeric core [24–26]. It is thought
that, since hLCB2 contains residues that are conserved
amongst other PLP-binding enzymes, it is essential for the
covalent attachment of PLP and SPT catalyses, whereas
hLCB1, which lacks the conserved residues, plays important
roles in catalysis and regulation [6].Mutations that knock out
SPT activity all together are lethal emphasizing the impor-
tance of de novo SL biosynthesis. However, linkage analysis
of patients/families with HSAN1 led to the identification
of disease-causing mutations in the hLCB1 subunits of SPT
[29, 30]. More recently additional disease-causing mutations
have been found in hLCB1 [33, 36–38] as well as in the
hLCB2a subunit [39]. Importantly, it was discovered that,
while mutations such as C133W and C133Y in hLCB1 greatly-
reduced SPT activity, the pathophysiology of HSAN1 is most
probably due to a gain of function that results in the ability to
utilize alanine and/or glycine as substrates [29, 30]. Patients
with the hLCB1 C133W/C133Y mutations generate deoxy-
SLs (1-deoxy and 1-deoxymethyl) that are present in high
concentrations compared to normal individuals. This was
subsequently confirmed in mouse models of the disease [32,
49]. It is thought that these neurotoxic deoxy-SLs are built
up over time to such concentrations that they lead to nerve
damage and breakdown. Since these deoxy-SLs cannot be
phosphorylated (to sphingosine 1-phosphate (S1P)), they can-
not be degraded by the S1P lyase and accumulate in cells. The
thinking is that different HSAN1 mutant SPTs (where either
the hLCB1 or hLCB2a proteins are altered) have differing
impacts on the activity with L-serine as a substrate, but where
10 BioMed Research International
there is a decrease, it is still above the threshold required
for cell survival. More importantly, these mutations have
differing influences on the promiscuity of themutant enzyme
such that it can also accept other amino acid substrates.
A discussion of this interesting model by SPT experts at a
symposium organised by a family afflicted by the disease
(Deater Symposium, Boston, April 2008) also suggested that
a potentially simple HSAN1 “cure (treatment)” would be
increasing dietary serine thereby increasing the intracellular
pool of L-serine to increase the ratio of serine/alanine thereby
reducing the synthesis of the toxic deoxy-SLs. Indeed, this
appears to be the case with the recent success of early clinical
trials of oral L-serine supplementation that reduced deoxy-SL
levels in serum and also led to an improvement in motor and
sensory performance in mice [50].
Rotthier and colleagues presented data that the new
HSAN1 hLCB2amutants (V359M, G382V, and I504F) reduce
SPT activity when expressed in HEK293 cells. They also
measured the deoxy-SL levels in HEK293 cells and the
lymphoblasts derived from HSAN1 patients carrying the
G382V and I504F mutations. In both cases deoxy-SL levels
were very high in agreement with the toxic SL hypothesis.We
also wanted to measure the impact of the small subunits on
the HSAN1 hLCB2a mutants. As well as activating basal SPT
activity, the small subunits modulate the acyl-CoA chain-
length specificity of the SPT [18].We found that coexpression
of either ssSPTa or ssSPTb increased basal activity of wild-
type heterodimers and those containing all three hLCB2a
mutants to varying degrees. In our recent paper we studied
the kinetics of SPT containing the hLCB1C133W HSAN1
mutant subunit and found that it had similar affinity for L-
serine as did wild-type SPT [31]. Surprisingly, the same was
true for L-alanine indicating that the major impact of the
C133W mutation is to enhance activation of the amino acid
substrate for condensation with the acyl-CoA substrate. A
similar kinetic analysis has not yet been done for the hLCB2a
mutants. We do not discuss the ability of these new HSAN1
mutants to use glycine and/or L-alanine as substrates here as it
requires a more detailed kinetic analysis of nine variables; the
four subunits (SPT1/2 and ssSPTa/b) with five substrates (L-
serine, glycine, L-alanine, and C14 and C16 acyl-CoAs), are
the subject of current work. However, we felt that valuable
insights would be gained by using the soluble bacterial SPT as
a model to make mutant mimics. We previously studied the
hLCB1 C133Wmutant bymapping this residue to N100 of the
S. paucimobilis SPT [10].The side chain of N100 is close to but
not in the active site of SPT, which lies at the subunit interface
of the soluble bacterial homodimer. Nevertheless, it does
contact the amide backbone of the key, conserved active site
lysine (K265) that binds the PLP as an internal aldimine, and
is also thought to act as the base that removes the proton from
C-𝛼 of L-serine (Figure 1). Replacement of N100 with either
the bulky tryptophan or tyrosine residue found inC133Wand
C133Ymight be expected to be disruptive to the structure and
activity of the homodimeric enzyme. Indeed, when we made
the N100W and N100Y mutants, we noted that PLP binding
was altered, and both the binding constants (𝑘
𝑚
) and catalytic
activities (𝑘cat) were lowered significantly compared to the
wild type. Moreover, we determined the crystal structure of
theN100Ymutant in its PLP-L-serine external aldimine form,
and a number of structural changes were observed; a key
residue (Arg378) that binds the L-serine carboxylate was in
the “swung out” conformation, the important PPATP loop
was in a twisted conformation, and the side chain of the
mutant mimic Y100 residue was now impacting the opposite
subunit. This study revealed that mutations in one subunit
can impact the overall structure and activity of the dimer and
provided us with some insights as to how HSAN1 causing
mutations may affect the human hLCB1/hLCB2a complex
[10].
Two of the three new hLCB2a HSAN1 causing mutations
(V359M and G382V) are found at residues that are strictly
conserved in LCB2s from human, mouse, fly, rat, zebra fish,
yeast, and bacterial SPT [39]. The third, I504, is less highly
conserved; in fly (Drosophilamelanogaster) it is amethionine,
and in bacterial Sp SPT enzyme it is a glycine. The HSAN1
causing mutations in hLCB2a (V359M, G382V, and I504F)
correspond to bacterial Sp SPT mutationsV246M, G268V
and G385F, respectively (Figure 2). G268 is three residues
away from the essential active site residue K265 and in the
3D structuremakes contact with the backbone of this residue.
It was not surprising that introduction of G268V resulted
in a drastic reduction in protein solubility, presumably due
to misfolding during recombinant expression. Modelling
studies reveal that this residue is also near to the side chain
of residue N100 from the opposite subunit of the homodimer
that we discussed above (Figure 5). In mutating G268 to
valine, polar contacts to the K265 residue are lost. A plausible
explanation for the misfolding of the G268V mutant is that
it disrupts the polar contacts with the key lysine residue. The
global fold of the protein could also be adversely affected by
an apparent steric clash between the side chain of valine in
position 268 and the backbone of Met78 (Figure 5(b)). In the
initial report of the holo-Sp SPT structure by Yard et al., active
site residues were identified, and G268 was also identified as
an essential active site residue which hydrogen bonds with
the backbone oxygen of K265 [7].The G268Vmodel predicts
that this H-bond is lost and is therefore not surprising that
this mutation has such a detrimental impact on the bacterial
enzyme (Figure 5(b)).
In contrast to the G268V mutant, modelling studies do
not give us clear insight as to the structural basis for the
HSAN1 phenotype in the V246M or G385F mutants. These
mutations appear to be more subtle. However, analysis of
the PLP cofactor binding and enzyme kinetics of these two
mutant mimics does provide some clue as to why these
changes would cause alterations of the hLCB2a subunit that
would lead to theHSAN1 phenotype. For the V246Mmutant,
structural models show that the V246 residue is far from
the PLP active site, and polar contacts with E232, A249, and
Q250 are retained after mutating the residue to a methionine
(Figure 6). The UV-visible spectrum of this mutant is very
similar to wild-type SPT and suggests that the PLP is bound
in a similar orientation to the wild-type enzyme (Figure 4).
The apparent 𝐾
𝑑
L-ser is unchanged by the incorporation of
the HSAN1 mutation, suggesting that, in this case, the key
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L-serine external aldimine intermediate is formed in the
same way as in the native SPT (Figure 1). However, this
mutation does have a detrimental effect on the observed
catalytic rate and efficiency, which again are 3-fold and 9-
fold lower than wild-type enzyme (Table 2). This V246M
mutant mimic also displays a significantly higher 𝐾
𝑚
for the
acyl-CoA thioester substrate, suggesting that binding of this
substrate is compromised at least subtly in this mutant. This
is useful information about a residue potentially involved in
binding the second substrate since, to date, we still do not
have a structure of the Sp SPT PLP complex with palmitoyl-
CoA bound.
In the structure of Sp SPT, residue G385 is surface-
exposed (Figure 7). For the G385F mutant it is plausible that
replacing glycine with the large, hydrophobic phenylalanine
residue may lead it to adopt an alternative conformation.
This has the potential to substantially affect the architecture
of the surrounding structure, such as the important PPATP
loop which undergoes large conformational changes during
the catalytic mechanism. However, without crystallographic
data for this mutant, it is impossible to confidently propose
any effect of a potential realignment at this position. In the
case of G385F, UV-visible analysis suggests that PLP binding
is altered and that the cofactor is in a different environment
compared to the wild-type enzyme. Furthermore, the appar-
ent 𝐾
𝑑
L-ser was ∼5 times higher for this mutant indicating
that serine binding is affected by thismutation (Table 2). Both
the catalytic rate and catalytic efficiency are also significantly
reduced (3-fold and 4-fold, resp.) demonstrating that catalysis
is also impaired.
5. Conclusion
Our results have shed light on how the three recently-
discovered HSAN1 causing hLCB2a mutants affect the SPT
complex in the presence of the activating small subunits
(ssSPTa and ssSPTb). To explore the impact of these muta-
tions on PLP binding, SPT structure, and activity, we also
use mutants of the soluble homodimeric bacterial SPT as
human SPTmimics to reveal that each mutant has a different
impact on the enzyme.These range from subtle alterations to
how PLP sits within the SPT active site, lowering substrate
binding and catalytic activity through to a complete loss
of solubility all brought about by a single change. New
SPT mutations that result in HSAN1 are being discovered
periodically; for example, another on the hLCB2a subunit,
A182P, was recently characterised that had reduced SPT
activity, a higher preference for L-alanine, and increased
plasma deoxy-SLs levels [42]. Exactly how these HSAN1
mutations cause the human hLCB1/hLCB2a/ssSPT complex
to lose its exquisite specificity for L-serine and also accept L-
alanine and glycine to form deoxy-SLs will require in-depth
structural and kinetic analyses of the purified wild-type and
mutant SPT complexes.
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